10.57
+0.38(+3.73%)
Currency In USD
| Previous Close | 10.19 |
| Open | 10.24 |
| Day High | 10.64 |
| Day Low | 10.07 |
| 52-Week High | 13.16 |
| 52-Week Low | 6.19 |
| Volume | 925,446 |
| Average Volume | 1.79M |
| Market Cap | 593.35M |
| PE | -42.28 |
| EPS | -0.25 |
| Moving Average 50 Days | 9.45 |
| Moving Average 200 Days | 8.74 |
| Change | 0.38 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $34.75 as of October 08, 2025 at a share price of $10.57. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $1,000.95 as of October 08, 2025 at a share price of $10.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 06, 2025 9:51 PM GMT
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)
GlobeNewswire Inc.
Sep 18, 2025 11:30 AM GMT
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA offers the esta
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
GlobeNewswire Inc.
Sep 04, 2025 11:30 AM GMT
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLYFFA’s differ